SuperworthEloxx Pharmaceuticals ELOX
- Market cap
- $51.7M
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY22 | Q2 FY22 | Q3 FY22 | Q4 FY22 | Q1 FY23 | Q2 FY23 | Q3 FY23 | Q4 FY23 | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| R&D | $7.9M+94% | $7.7M+34% | $4.9M−6% | $3.3M−58% | $3.5M−56% | $2.3M−69% | $1.3M−74% | $1.5M−54% | $510K | $898K | $1.7M | $2.8M |
| SG&A | $3.1M−30% | $2.6M−64% | $2.3M−55% | $2.7M−27% | $2M−35% | $1.8M−32% | $2.4M+6% | $2.5M−8% | $712K | $684K | $2.1M | $1.6M |
| −$11M+30% | −$10.3M−71% | −$7.1M−30% | −$6M−48% | −$5.5M−50% | −$4.1M−60% | −$3.6M−49% | −$4M−33% | −$1.2M | −$1.6M | −$3.8M | −$4.5M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $500K | $300K | $100K | $100K |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Net income | −$11.6M+34% | −$10.6M−71% | −$7.5M−24% | −$6.3M−48% | −$6.2M−46% | −$4.3M−59% | −$3.6M−52% | −$2.9M−54% | −$1.7M | −$1.9M | −$3.8M | −$4.5M |
| −$58.96−39% | −$53.90−77% | −$38.17−21% | −$32.12−48% | −$31.68−46% | −$21.56−60% | −$14.41−62% | −$10.12−69% | −$4.95 | −$5.45 | −$0.88 | −$0.66 | |
| 196.9K+116% | 196.9K+31% | 196.9K+1% | 196.9K+0% | 196.9K+0% | 201.1K+2% | 249.8K+27% | 285.8K+45% | 346K | 347K | 4.4M | 6.8M |
EPS, diluted: 12 periods, Q4 FY12 to Q4 FY23: quarter's net income to common over its shares, to the cent.
Diluted shares: 11 periods, Q4 FY12 to Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x40).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Eloxx Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ELOXEloxx Pharmaceuticals | $51.7M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $83.3M | 12.8× | 18.1× | 1.4× | +7% | 6.8% |
More on Eloxx Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .